1. Use of Interferon-Gamma Release Assays to Calculate the Annual Risk of Tuberculosis Infection
- Author
-
Francisco-Javier Roig, Alicia Lacoma, Amparo Escribano, Irene Latorre, Irene Mialdea, Nuria Díez, José Domínguez, Mar Serra-Vidal, Jessica Diaz, and Empar Giner
- Subjects
Male ,Microbiology (medical) ,medicine.medical_specialty ,Tuberculosis ,Cross-sectional study ,Tuberculin ,Risk Assessment ,Annual incidence ,Cohort Studies ,Internal medicine ,Prevalence ,medicine ,Humans ,Interferon gamma ,Child ,Diagnostic Tests, Routine ,Tuberculin Test ,business.industry ,Incidence ,Incidence (epidemiology) ,bacterial infections and mycoses ,medicine.disease ,Cross-Sectional Studies ,Infectious Diseases ,Spain ,Pediatrics, Perinatology and Child Health ,Immunology ,Female ,business ,Risk assessment ,Interferon-gamma Release Tests ,Cohort study ,medicine.drug - Abstract
The objective was to assess the annual risk of tuberculosis infection by means of tuberculin skin testing (TST) in children, evaluating whether QuantiFERON-TB Gold In-Tube (QFN-G-IT) could improve the accuracy. On the basis of the positive TST results, the global annual incidence was estimated at 0.78%, with an increase in the prevalence from 0.64% to 1.68% in 2 years. However, QFN-G-IT was only positive in 6 of the 25 children with positive TST. The confirmation of the positive TST results by QFN-G-IT provided more accurate annual incidence estimation.
- Published
- 2015
- Full Text
- View/download PDF